Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-diphenylmethoxy-n,n-dimethylethylamine
2. Allerdryl
3. Benadryl
4. Benhydramin
5. Benylin
6. Benzhydramine
7. Citrate, Diphenhydramine
8. Dimedrol
9. Diphenhydramine
10. Diphenhydramine Citrate (1:1)
11. Diphenhydramine Hydrochloride
12. Diphenylhydramin
13. Diphenylhydramine
14. Dormin
15. Hydrochloride, Diphenhydramine
1. 88637-37-0
2. 2-(benzhydryloxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate
3. Diphenhydramine Citrate [usp]
4. Diphenhydramine (citrate)
5. 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic Acid
6. 4od433s209
7. 2-(diphenylmethoxy)-n,n-dimethylethylamine Citrate (1:1)
8. Diphenhydramine Citrate (usp)
9. Ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
10. Unii-4od433s209
11. Einecs 289-432-0
12. Schembl322306
13. Chembl1201089
14. Dtxsid80237211
15. Bcp12478
16. 2-(benzhydryloxy)-n,n-dimethylethanamine2-hydroxypropane-1,2,3-tricarboxylate
17. Akos016005048
18. Diphenhydramine Citrate [mart.]
19. Diphenhydramine Citrate [vandf]
20. 2-benzhydryloxy-n,n-dimethylethanamine,2-hydroxypropane-1,2,3-tricarboxylic Acid
21. Diphenhydramine Citrate [usp-rs]
22. Diphenhydramine Citrate [who-dd]
23. Diphenhydramine Citrate [orange Book]
24. D03854
25. Diphenhydramine Citrate [usp Monograph]
26. 637d370
27. Q5402419
28. (2-(diphenylmethoxy)ethyl)dimethylammonium Dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
Molecular Weight | 447.5 g/mol |
---|---|
Molecular Formula | C23H29NO8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 11 |
Exact Mass | 447.18931688 g/mol |
Monoisotopic Mass | 447.18931688 g/mol |
Topological Polar Surface Area | 145 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 439 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Anesthetics, Local
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)
Sleep Aids, Pharmaceutical
Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Diphenhydramine Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diphenhydramine Citrate, including repackagers and relabelers. The FDA regulates Diphenhydramine Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diphenhydramine Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Diphenhydramine Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Diphenhydramine Citrate supplier is an individual or a company that provides Diphenhydramine Citrate active pharmaceutical ingredient (API) or Diphenhydramine Citrate finished formulations upon request. The Diphenhydramine Citrate suppliers may include Diphenhydramine Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Diphenhydramine Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Diphenhydramine Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Diphenhydramine Citrate active pharmaceutical ingredient (API) in detail. Different forms of Diphenhydramine Citrate DMFs exist exist since differing nations have different regulations, such as Diphenhydramine Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Diphenhydramine Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Diphenhydramine Citrate USDMF includes data on Diphenhydramine Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Diphenhydramine Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Diphenhydramine Citrate suppliers with USDMF on PharmaCompass.
A Diphenhydramine Citrate written confirmation (Diphenhydramine Citrate WC) is an official document issued by a regulatory agency to a Diphenhydramine Citrate manufacturer, verifying that the manufacturing facility of a Diphenhydramine Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Diphenhydramine Citrate APIs or Diphenhydramine Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Diphenhydramine Citrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Diphenhydramine Citrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Diphenhydramine Citrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Diphenhydramine Citrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Diphenhydramine Citrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Diphenhydramine Citrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Diphenhydramine Citrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Diphenhydramine Citrate suppliers with NDC on PharmaCompass.
Diphenhydramine Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Diphenhydramine Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diphenhydramine Citrate GMP manufacturer or Diphenhydramine Citrate GMP API supplier for your needs.
A Diphenhydramine Citrate CoA (Certificate of Analysis) is a formal document that attests to Diphenhydramine Citrate's compliance with Diphenhydramine Citrate specifications and serves as a tool for batch-level quality control.
Diphenhydramine Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Diphenhydramine Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Diphenhydramine Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Diphenhydramine Citrate EP), Diphenhydramine Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diphenhydramine Citrate USP).
LOOKING FOR A SUPPLIER?